Li T, et al. - To define risk factors, trends, and variability related to the development of bortezomib-induced peripheral neuropathy (BIPN), which is common toxicity related to the management of multiple myeloma, researchers undertook a systematic review of phase III trials identified from Medline, PubMed, Cochrane Central Register of Controlled Trials, Embase, Scopus, and Web of Science. As per findings, the overall incidence of neuropathy and of severe neuropathy (grade 3-4) ranged from 8.4% to 80.5% and from 1% to 33.2%, respectively. A reduced neuropathy incidence was revealed in relation to bortezomib regimens with decreased dose intensity. Higher rates of BIPN were reported in relation to increased cumulative dosing levels, intravenous vs subcutaneous administration and combination therapy with thalidomide. By these observations, BIPN emerged as significant toxicity. To capture the incidence and severity of BIPN, there is a need for more sensitive measures. A reduction in the number of cancer survivors living with residual treatment side effects will be achieved by acquiring an improved understanding of risk factors and reversibility profiles.